Hereditary Angioedema Therapeutic Market Insights, Global Outlook and Forecast 2022-2028
Hereditary Angioedema Therapeutic Market Insights, Global Outlook and Forecast 2022-2028
The Hereditary Angioedema Therapeutic study provides a comprehensive overview of safety standards, market penetration, and innovation pipelines across major economies.
Exclusive deal : 20% Instant discount on Direct purchases! Don't wait—claim your discount today!
Hereditary Angioedema Therapeutic is the treatment for Hereditary Angioedema. Growing cases of hereditary angioedema (HAE) globally is a key market driver.
The latest research study released by Market IntelliX evaluates market size and forecasts of Hereditary Angioedema Therapeutic in Global, including the following market information:
Global Hereditary Angioedema Therapeutic Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Hereditary Angioedema Therapeutic market was valued at 2149.1 million in 2021 and is projected to reach US$ 3000 million by 2028, at a CAGR of 4.9% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Intravenous Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Hereditary Angioedema Therapeutic include BioCryst Pharma, Ionis Pharma, Pharming Group, CSL Limited, Shire, Attune Pharma, Adverum Biotechnologies and KalVista Pharma, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MI has surveyed the Hereditary Angioedema Therapeutic companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Market Segmentations:
Global Hereditary Angioedema Therapeutic Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Hereditary Angioedema Therapeutic Market Segment Percentages, by Type, 2021 (%)
Intravenous
Subcutaneous
Oral
Global Hereditary Angioedema Therapeutic Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Hereditary Angioedema Therapeutic Market Segment Percentages, by Application, 2021 (%)
Hospitals
Clinics
Others
Global Hereditary Angioedema Therapeutic Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Hereditary Angioedema Therapeutic Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Hereditary Angioedema Therapeutic revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Hereditary Angioedema Therapeutic revenues share in global market, 2021 (%)
The report presents profiles of competitors in the market, Some of the prominent key players covered:
BioCryst Pharma
Ionis Pharma
Pharming Group
CSL Limited
Shire
Attune Pharma
Adverum Biotechnologies
KalVista Pharma
Key Takeaways from this Report
Evaluate market potential through analyzing growth rates (CAGR %), Volume (Units) and Value ($M) data given at country level – for product types, end use applications and by different industry verticals.
Understand the different dynamics influencing the market – key driving factors, challenges and hidden opportunities.
Get in-depth insights on your competitor performance – market shares, strategies, financial benchmarking, product benchmarking, SWOT and more.
Analyze the sales and distribution channels across key geographies to improve top-line revenues.
Understand the industry supply chain with a deep-dive on the value augmentation at each step, in order to optimize value and bring efficiencies in your processes.
Get a quick outlook on the market entropy – M&A’s, deals, partnerships, product launches of all key players for the past 4 years.
Evaluate the supply-demand gaps, import-export statistics and regulatory landscape for more than top 20 countries globally for the market.
1 Introduction to Research & Analysis Reports
1.1 Hereditary Angioedema Therapeutic Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Hereditary Angioedema Therapeutic Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Hereditary Angioedema Therapeutic Overall Market Size
2.1 Global Hereditary Angioedema Therapeutic Market Size: 2021 VS 2028
2.2 Global Hereditary Angioedema Therapeutic Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Hereditary Angioedema Therapeutic Players in Global Market
3.2 Top Global Hereditary Angioedema Therapeutic Companies Ranked by Revenue
3.3 Global Hereditary Angioedema Therapeutic Revenue by Companies
3.4 Top 3 and Top 5 Hereditary Angioedema Therapeutic Companies in Global Market, by Revenue in 2021
3.5 Global Companies Hereditary Angioedema Therapeutic Product Type
3.6 Tier 1, Tier 2 and Tier 3 Hereditary Angioedema Therapeutic Players in Global Market
3.6.1 List of Global Tier 1 Hereditary Angioedema Therapeutic Companies
3.6.2 List of Global Tier 2 and Tier 3 Hereditary Angioedema Therapeutic Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Type - Global Hereditary Angioedema Therapeutic Market Size Markets, 2021 & 2028
4.1.2 Intravenous
4.1.3 Subcutaneous
4.1.4 Oral
4.2 By Type - Global Hereditary Angioedema Therapeutic Revenue & Forecasts
4.2.1 By Type - Global Hereditary Angioedema Therapeutic Revenue, 2017-2022
4.2.2 By Type - Global Hereditary Angioedema Therapeutic Revenue, 2023-2028
4.2.3 By Type - Global Hereditary Angioedema Therapeutic Revenue Market Share, 2017-2028
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Hereditary Angioedema Therapeutic Market Size, 2021 & 2028
5.1.2 Hospitals
5.1.3 Clinics
5.1.4 Others
5.2 By Application - Global Hereditary Angioedema Therapeutic Revenue & Forecasts
5.2.1 By Application - Global Hereditary Angioedema Therapeutic Revenue, 2017-2022
5.2.2 By Application - Global Hereditary Angioedema Therapeutic Revenue, 2023-2028
5.2.3 By Application - Global Hereditary Angioedema Therapeutic Revenue Market Share, 2017-2028
6 Sights by Region
6.1 By Region - Global Hereditary Angioedema Therapeutic Market Size, 2021 & 2028
6.2 By Region - Global Hereditary Angioedema Therapeutic Revenue & Forecasts
6.2.1 By Region - Global Hereditary Angioedema Therapeutic Revenue, 2017-2022
6.2.2 By Region - Global Hereditary Angioedema Therapeutic Revenue, 2023-2028
6.2.3 By Region - Global Hereditary Angioedema Therapeutic Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Hereditary Angioedema Therapeutic Revenue, 2017-2028
6.3.2 US Hereditary Angioedema Therapeutic Market Size, 2017-2028
6.3.3 Canada Hereditary Angioedema Therapeutic Market Size, 2017-2028
6.3.4 Mexico Hereditary Angioedema Therapeutic Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Hereditary Angioedema Therapeutic Revenue, 2017-2028
6.4.2 Germany Hereditary Angioedema Therapeutic Market Size, 2017-2028
6.4.3 France Hereditary Angioedema Therapeutic Market Size, 2017-2028
6.4.4 U.K. Hereditary Angioedema Therapeutic Market Size, 2017-2028
6.4.5 Italy Hereditary Angioedema Therapeutic Market Size, 2017-2028
6.4.6 Russia Hereditary Angioedema Therapeutic Market Size, 2017-2028
6.4.7 Nordic Countries Hereditary Angioedema Therapeutic Market Size, 2017-2028
6.4.8 Benelux Hereditary Angioedema Therapeutic Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Hereditary Angioedema Therapeutic Revenue, 2017-2028
6.5.2 China Hereditary Angioedema Therapeutic Market Size, 2017-2028
6.5.3 Japan Hereditary Angioedema Therapeutic Market Size, 2017-2028
6.5.4 South Korea Hereditary Angioedema Therapeutic Market Size, 2017-2028
6.5.5 Southeast Asia Hereditary Angioedema Therapeutic Market Size, 2017-2028
6.5.6 India Hereditary Angioedema Therapeutic Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Hereditary Angioedema Therapeutic Revenue, 2017-2028
6.6.2 Brazil Hereditary Angioedema Therapeutic Market Size, 2017-2028
6.6.3 Argentina Hereditary Angioedema Therapeutic Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Hereditary Angioedema Therapeutic Revenue, 2017-2028
6.7.2 Turkey Hereditary Angioedema Therapeutic Market Size, 2017-2028
6.7.3 Israel Hereditary Angioedema Therapeutic Market Size, 2017-2028
6.7.4 Saudi Arabia Hereditary Angioedema Therapeutic Market Size, 2017-2028
6.7.5 UAE Hereditary Angioedema Therapeutic Market Size, 2017-2028
7 Players Profiles
7.1 BioCryst Pharma
7.1.1 BioCryst Pharma Corporate Summary
7.1.2 BioCryst Pharma Business Overview
7.1.3 BioCryst Pharma Hereditary Angioedema Therapeutic Major Product Offerings
7.1.4 BioCryst Pharma Hereditary Angioedema Therapeutic Revenue in Global Market (2017-2022)
7.1.5 BioCryst Pharma Key News
7.2 Ionis Pharma
7.2.1 Ionis Pharma Corporate Summary
7.2.2 Ionis Pharma Business Overview
7.2.3 Ionis Pharma Hereditary Angioedema Therapeutic Major Product Offerings
7.2.4 Ionis Pharma Hereditary Angioedema Therapeutic Revenue in Global Market (2017-2022)
7.2.5 Ionis Pharma Key News
7.3 Pharming Group
7.3.1 Pharming Group Corporate Summary
7.3.2 Pharming Group Business Overview
7.3.3 Pharming Group Hereditary Angioedema Therapeutic Major Product Offerings
7.3.4 Pharming Group Hereditary Angioedema Therapeutic Revenue in Global Market (2017-2022)
7.3.5 Pharming Group Key News
7.4 CSL Limited
7.4.1 CSL Limited Corporate Summary
7.4.2 CSL Limited Business Overview
7.4.3 CSL Limited Hereditary Angioedema Therapeutic Major Product Offerings
7.4.4 CSL Limited Hereditary Angioedema Therapeutic Revenue in Global Market (2017-2022)
7.4.5 CSL Limited Key News
7.5 Shire
7.5.1 Shire Corporate Summary
7.5.2 Shire Business Overview
7.5.3 Shire Hereditary Angioedema Therapeutic Major Product Offerings
7.5.4 Shire Hereditary Angioedema Therapeutic Revenue in Global Market (2017-2022)
7.5.5 Shire Key News
7.6 Attune Pharma
7.6.1 Attune Pharma Corporate Summary
7.6.2 Attune Pharma Business Overview
7.6.3 Attune Pharma Hereditary Angioedema Therapeutic Major Product Offerings
7.6.4 Attune Pharma Hereditary Angioedema Therapeutic Revenue in Global Market (2017-2022)
7.6.5 Attune Pharma Key News
7.7 Adverum Biotechnologies
7.7.1 Adverum Biotechnologies Corporate Summary
7.7.2 Adverum Biotechnologies Business Overview
7.7.3 Adverum Biotechnologies Hereditary Angioedema Therapeutic Major Product Offerings
7.7.4 Adverum Biotechnologies Hereditary Angioedema Therapeutic Revenue in Global Market (2017-2022)
7.7.5 Adverum Biotechnologies Key News
7.8 KalVista Pharma
7.8.1 KalVista Pharma Corporate Summary
7.8.2 KalVista Pharma Business Overview
7.8.3 KalVista Pharma Hereditary Angioedema Therapeutic Major Product Offerings
7.8.4 KalVista Pharma Hereditary Angioedema Therapeutic Revenue in Global Market (2017-2022)
7.8.5 KalVista Pharma Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
Research Methodology:
Hereditary Angioedema Therapeutic Market Size Estimation
To estimate market size and trends, we use a combination of top-down and bottom-up methods. This allows us to evaluate the market from various perspectives—by company, region, product type, and end users.
Our estimates are based on actual sales data, excluding any discounts. Segment breakdowns and market shares are calculated using weighted averages based on usage rates and average prices. Regional insights are determined by how widely a product or service is adopted in each area.
Key companies are identified through secondary sources like industry reports and company filings. We then verify revenue estimates and other key data points through primary research, including interviews with industry experts, company executives, and decision-makers.
We take into account all relevant factors that could influence the market and validate our findings with real-world input. Our final insights combine both qualitative and quantitative data to provide a well-rounded view. Please note, these estimates do not account for unexpected changes such as inflation, economic downturns, or policy shifts.
Data Source
Secondary Sources
This study draws on a wide range of secondary sources, including press releases, annual reports, non-profit organizations, industry associations, government agencies, and customs data. We also referred to reputable databases and directories such as Bloomberg, Wind Info, Hoovers, Factiva, Trading Economics, Statista, and others. Additional references include investor presentations, company filings (e.g., SEC), economic data, and documents from regulatory and industry bodies.
These sources were used to gather technical and market-focused insights, identify key players, analyze market segmentation and classification, and track major trends and developments across industries.
| Market Size |
|
|
| Market Position of Top Company |
|
|
| Qualitative Analysis |
|
|
Primary Sources
As part of our primary research, we interviewed a variety of stakeholders from both the supply and demand sides to gather valuable qualitative and quantitative insights.
On the supply side, we spoke with product manufacturers, competitors, industry experts, research institutions, distributors, traders, and raw material suppliers. On the demand side, we engaged with business leaders, marketing and sales heads, technology and innovation directors, supply chain executives, and end users across key organizations.
These conversations helped us better understand market segmentation, pricing, applications, leading players, supply chains, demand trends, industry outlook, and key market dynamics—including risks, opportunities, barriers, and strategic developments.
Key Data Information from Primary Sources
| Primary Sources | Parameters | Key Data |
| Market Segments(by Application, by Type) |
|
|
| Total Market |
|
|